18 Facts About Angelika Amon

Angelika Amon was an Austrian American molecular and cell biologist, and the Kathleen and Curtis Marble Professor in Cancer Research at the Massachusetts Institute of Technology in Cambridge, Massachusetts, United States.

Angelika Amon was elected to the American Academy of Arts and Sciences in 2017.

Angelika Amon displayed an early interest in plant and animal biology as a child, keeping a notebook full of newspaper clippings, and was motivated to study biology after learning about Mendelian genetics and seeing time-lapse micrographs of the division of plant cells in middle school.

Angelika Amon received an undergraduate degree in biology from the University of Vienna.

Angelika Amon continued her doctoral work there beginning in 1989 under a newly hired Kim Nasmyth at the Research Institute of Molecular Pathology, receiving a PhD in 1993.

Angelika Amon left Austria for the United States in 1994, joining the Whitehead Institute in Cambridge, Massachusetts as a postdoctoral researcher.

Angelika Amon was named a Whitehead Fellow in 1996, which allowed her to start her own laboratory at the Institute.

Angelika Amon became an associate investigator for the Howard Hughes Medical Institute in 2000, and was promoted to full professor at MIT in 2007; she had earlier achieved tenure as an assistant professor.

Angelika Amon was listed as a member of the Editorial Board for Current Biology in 2016, but no longer appears in this position as of 2019.

Angelika Amon served on the Scientific Advisory Board of the Research Institute of Molecular Pathology from 2009 to 2019.

Angelika Amon was elected to the American Academy of Arts and Sciences in 2017, by which time she had been named the Kathleen and Curtis Marble Professor of Cancer Research at MIT.

Angelika Amon was conferred the Vilcek Prize two years later, in recognition of her as one who had "made extraordinary contributions to their fields" while being a foreign-born researcher in the United States.

Angelika Amon was 53, and suffered from ovarian cancer in the two-and-a-half years leading up to her death.

Angelika Amon's research has investigated how cells control and organize the segregation of their chromosomes during cell division.

Angelika Amon's team demonstrated that CDC20 is the target protein in the spindle checkpoint during mitosis.

Angelika Amon identified two regulatory networks that promote the release of CDC14 which have the potential to identify the mechanisms that control the final stages of the mitotic cell cycle.

Angelika Amon has examined trisomy in the mouse as a model of mammalian cell growth and physiology and demonstrated that mammalian aneuploidy results in a stress response analogous to yeast aneuploidy.

Angelika Amon found that aneuploidy can interfere with a cell's normal DNA repair mechanisms, allowing mutations to accumulate in tumor cells.